1,235 Shares in Zoetis Inc. (NYSE:ZTS) Bought by Ethos Financial Group LLC

Ethos Financial Group LLC bought a new stake in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,235 shares of the company’s stock, valued at approximately $244,000.

A number of other institutional investors have also made changes to their positions in ZTS. Wellington Management Group LLP grew its holdings in shares of Zoetis by 2.5% in the 3rd quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after acquiring an additional 297,044 shares in the last quarter. Northern Trust Corp raised its stake in shares of Zoetis by 3.3% during the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock worth $1,068,804,000 after purchasing an additional 196,771 shares in the last quarter. Royal Bank of Canada boosted its holdings in shares of Zoetis by 3.1% in the 3rd quarter. Royal Bank of Canada now owns 3,026,518 shares of the company’s stock valued at $526,553,000 after buying an additional 91,713 shares during the last quarter. Blair William & Co. IL grew its stake in shares of Zoetis by 1.4% in the third quarter. Blair William & Co. IL now owns 2,428,509 shares of the company’s stock valued at $422,512,000 after buying an additional 32,918 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in Zoetis by 0.5% during the third quarter. Principal Financial Group Inc. now owns 2,126,090 shares of the company’s stock worth $369,736,000 after buying an additional 10,153 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ZTS. Piper Sandler restated an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Barclays dropped their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. The Goldman Sachs Group decreased their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday. Stifel Nicolaus dropped their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Finally, HSBC decreased their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $211.75.

Zoetis Stock Up 1.9 %

Shares of NYSE ZTS traded up $3.21 during trading on Thursday, reaching $168.13. The company had a trading volume of 2,108,446 shares, compared to its average volume of 3,184,266. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30. The business’s 50-day moving average is $166.94 and its 200 day moving average is $178.83. The stock has a market cap of $76.72 billion, a PE ratio of 32.40, a P/E/G ratio of 2.57 and a beta of 0.86.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.04. The business had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.31 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the transaction, the executive vice president now directly owns 20,417 shares of the company’s stock, valued at approximately $4,037,257.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 2,209 shares of company stock valued at $371,293. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.